Trial
NCT02875067
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
Merck Sharp & Dohme LLC
Condition
Relapsed Hodgkin Lymphoma
Intervention
Pembrolizumab
Why stopped
Merck's decision for early termination of the data
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-14